Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) increased during the last reporting period, rising from 7.37M to 7.83M. This put 23.51% of the company's publicly available shares short.

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

Therefore, the Zacks rating upgrade for Ginkgo Bioworks basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.